Yüklüyor......
Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival. Although generally well tolerated, a minority of patients discontinue therapy due to gastr...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer Healthcare
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4003341/ https://ncbi.nlm.nih.gov/pubmed/24639005 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-014-0112-1 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|